WallStSmart

Plexus Corp (PLXS)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Plexus Corp generates 1494% more annual revenue ($4.13B vs $258.90M). PLXS leads profitability with a 4.3% profit margin vs -15.5%. PLXS earns a higher WallStSmart Score of 51/100 (C-).

PLXS

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 5.5Value: 6.0Quality: 8.5
Piotroski: 6/9Altman Z: 3.24

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

PLXSUndervalued (+71.3%)

Margin of Safety

+71.3%

Fair Value

$713.29

Current Price

$250.58

$462.71 discount

UndervaluedFair: $713.29Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

PLXS2 strengths · Avg: 9.5/10
Altman Z-ScoreHealth
3.2410/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.159/10

Conservative balance sheet, low leverage

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

PLXS4 concerns · Avg: 3.3/10
PEG RatioValuation
2.094/10

Expensive relative to growth rate

P/E RatioValuation
39.0x4/10

Premium valuation, high expectations priced in

Profit MarginProfitability
4.3%3/10

4.3% margin — thin

Free Cash FlowQuality
$-50.58M2/10

Negative free cash flow — burning cash

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : PLXS

The strongest argument for PLXS centers on Altman Z-Score, Debt/Equity.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : PLXS

The primary concerns for PLXS are PEG Ratio, P/E Ratio, Profit Margin. Thin 4.3% margins leave little buffer for downturns.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

PLXS profiles as a value stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor ELECTRONIC COMPONENTS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

PLXS scores higher overall (51/100 vs 41/100). ZEPP offers better value entry with a 48.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Plexus Corp

TECHNOLOGY · ELECTRONIC COMPONENTS · USA

Plexus Corp. The company is headquartered in Neenah, Wisconsin.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?